Figure 8
GB235 in combination treatment with Trastuzumab inhibited tumor growth in the NCI-N87 gastric xenograft tumor model. BALB/c nude mice bearing NCI-N87 tumors were randomized into treatment and control groups when tumor volumes reached 100∼150 mm3 (n = 10 mice/group) and intraperitoneally treated with: (A) Trastuzumab alone (20 mg/kg), combination treatment of GB235 and Trastuzumab (5 + 20 mg/kg), (B) GB235 and Trastuzumab (10 + 20 mg/kg). The same dose ratios of combination treatment with Pertuzumab and Trastuzumab as control. Tumor volume is expressed as the mean ± SEM. ***p < 0.001.
